HSD17B13 and metabolic dysfunction-associated steatotic liver disease: Two independent studies revealed that the hepatic expression of HSD17B13 was significantly induced in patients with NAFLD relative to that in healthy individuals (Su et al., 2014; Ma et al., 2019).